SOTIO's Dendritic Cell Vaccines Have Promise In Ovary And Lung Cancer
Executive Summary
Interim Phase II data has shown that SOTIO's dendritic cell-based cancer vaccine candidates have efficacy in patients with ovarian cancer and non-small cell lung cancer.
You may also be interested in...
Autolus Faces Life After Woodford With New Czech Backer
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.
Pipeline Watch: Phase III Progress With Semaglutide, Tecentriq And Epidaza
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.